Johansson Martin, Arlestig Lisbeth, Möller Bozena, Rantapää-Dahlqvist Solbritt
University Hospital, Umeå, and Sunderbyn Hospital, Luleå, Sweden.
Arthritis Rheum. 2005 Jun;52(6):1665-9. doi: 10.1002/art.21058.
To analyze the association of the PD-1.3 polymorphism within the PDCD1 gene in patients with systemic lupus erythematosus (SLE) from the homogeneous population in northern Sweden. The PD-1.3A allele was analyzed in relation to disease manifestations and severity representing various phenotypes of SLE.
The study group comprised 260 patients fulfilling at least 4 of the American College of Rheumatology (ACR) criteria for SLE during 1 year. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics/ACR damage index scores were recorded. Population-based, randomly selected individuals (n = 670) from the same geographic area served as controls. DNA was extracted from blood samples from both patients and controls and was genotyped for the PD-1.3 A/G polymorphism, using an ABI Prism 7900HT Sequence Detection System.
The frequency distribution of alleles, carriers, or genotypes did not differ between patients and controls. The PD-1.3A allele and carriage of the A allele were highly associated with renal disorder (ACR criterion 7) (P = 0.005, odds ratio [OR] 2.71 [95% confidence interval (95% CI) 1.32-5.55] and P = 0.012, OR 2.62 [95% CI 1.28-5.35], respectively). In regression analysis adjusted for sex and age at disease onset, carriage of the A allele remained significantly associated with renal disorder (P = 0.002, OR 3.54 [95% CI 1.56-8.01]). The presence of proteinuria, as measured by the SLEDAI score, and the presence of renal damage were also significantly associated with carriage of the A allele (P = 0.007, OR 3.88 [95% CI 1.44-10.47] and P = 0.021, OR 2.98 [95% CI 1.18-7.54], respectively).
The PD-1.3A allele is associated with renal manifestations in SLE patients from northern Sweden but not with susceptibility to SLE per se.
分析瑞典北部同质人群中系统性红斑狼疮(SLE)患者程序性死亡蛋白1(PDCD1)基因内PD - 1.3多态性的关联。分析PD - 1.3A等位基因与代表SLE各种表型的疾病表现和严重程度之间的关系。
研究组包括在1年内符合美国风湿病学会(ACR)至少4条SLE标准的260例患者。记录系统性红斑狼疮疾病活动指数(SLEDAI)和系统性红斑狼疮国际协作临床/ACR损伤指数评分。来自同一地理区域的基于人群随机选择的个体(n = 670)作为对照。从患者和对照的血样中提取DNA,并使用ABI Prism 7900HT序列检测系统对PD - 1.3 A/G多态性进行基因分型。
患者和对照之间等位基因、携带者或基因型的频率分布没有差异。PD - 1.3A等位基因和A等位基因的携带与肾脏疾病(ACR标准7)高度相关(P = 0.005,比值比[OR] 2.71 [95%置信区间(95%CI)1.32 - 5.55]和P = 0.012,OR 2.62 [95%CI 1.28 - 5.35])。在针对疾病发作时的性别和年龄进行校正的回归分析中,A等位基因的携带仍与肾脏疾病显著相关(P = 0.002,OR 3.54 [95%CI 1.56 - 8.01])。通过SLEDAI评分测量的蛋白尿的存在以及肾脏损伤的存在也与A等位基因的携带显著相关(分别为P = 0.007,OR 3.88 [95%CI 1.44 - 10.47]和P = 0.021,OR 2.98 [95%CI 1.18 - 7.54])。
PD - 1.3A等位基因与瑞典北部SLE患者的肾脏表现相关,但与SLE本身的易感性无关。